Targeting the FABP4-PPARγ axis with IPA improves obesity-related glomerulopathy

Area of Science:

• Nephrology
• Metabolic Diseases
• Pharmacology

Background:

• Obesity-related glomerulopathy (ORG) is a kidney disease linked to obesity, marked by fibrosis and lipid buildup.
• The molecular drivers of ORG are not fully understood, requiring new therapeutic strategies.

Purpose of the Study:

• To investigate the therapeutic potential of indole-3-propionic acid (IPA) in ORG.
• To explore IPA's effects on key proteins, including fatty acid-binding protein 4 (FABP4) and peroxisome proliferator-activated receptor γ (PPARγ).

Main Methods:

• Virtual screening identified FABP4 as a potential IPA target.
• Protein expression and interaction studies were conducted.
• IPA's impact on renal fibrosis and lipid deposition was assessed in a PPARγ-dependent manner.

Main Results:

• IPA did not change FABP4 expression but increased PPARγ protein levels.
• IPA competitively binds FABP4, disrupting the FABP4-PPARγ complex.
• This interaction stabilizes PPARγ, reducing renal fibrosis and lipid accumulation.

Conclusions:

• IPA modulates the FABP4-PPARγ axis, offering a potential therapeutic approach for ORG.
• Targeting the FABP4-PPARγ interaction with IPA may mitigate obesity-induced kidney damage.